Form D · Biotechnology
Nvigen, Inc.
Sunnyvale, CA · CIK 0001524709
Offering snapshot reported Mar 18, 2014 · SEC filing
- Reported sold
- $1.12M Offering amount: $1.49M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 8, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 18, 2014 | Initial | $1,116,749 | No comparison | 13 | SEC filing |
| Jul 22, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-213842
This filing covers the purchase and sale of Series B Preferred Stock and the Common Stock issuable upon conversion of such Preferred Stock.
Source: Form D, filed Mar 18, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aihua Fu | Director, Executive, Promoter |
| Xiangdong Jin | Executive |
| Guo Liang Yu | Director |
| Guoliang Yu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
265 Sobrante Way, Suite H
Sunnyvale, CA, 94086
Sunnyvale, CA, 94086